Search

Your search keyword '"Gamis, Alan S."' showing total 950 results
Start Over Author "Gamis, Alan S." Search Limiters Academic (Peer-Reviewed) Journals
950 results on '"Gamis, Alan S."'

3. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Author

Huang, Benjamin J, Smith, Jenny L, Farrar, Jason E, Wang, Yi-Cheng, Umeda, Masayuki, Ries, Rhonda E, Leonti, Amanda R, Crowgey, Erin, Furlan, Scott N, Tarlock, Katherine, Armendariz, Marcos, Liu, Yanling, Shaw, Timothy I, Wei, Lisa, Gerbing, Robert B, Cooper, Todd M, Gamis, Alan S, Aplenc, Richard, Kolb, E Anders, Rubnitz, Jeffrey, Ma, Jing, Klco, Jeffery M, Ma, Xiaotu, Alonzo, Todd A, Triche, Timothy, and Meshinchi, Soheil

Subjects
Genetics, Hematology, Rare Diseases, Childhood Leukemia, Human Genome, Stem Cell Research, Cancer, Pediatric, Pediatric Cancer, Pediatric Research Initiative, Clinical Research, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Biomarkers, Child, Gene Expression Profiling, Humans, Leukemia, Myeloid, Acute, Neoplastic Stem Cells, RNA, Recurrence
Abstract

Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional risk prediction model for pediatric AML, we perform RNA-sequencing on 1503 primary diagnostic samples. While a 17 gene leukemia stem cell signature (LSC17) is predictive in our aggregated pediatric study population, LSC17 is no longer predictive within established cytogenetic and molecular (cytomolecular) risk groups. Therefore, we identify distinct LSC signatures on the basis of AML cytomolecular subtypes (LSC47) that were more predictive than LSC17. Based on these findings, we build a robust relapse prediction model within a training cohort and then validate it within independent cohorts. Here, we show that LSC47 increases the predictive power of conventional risk stratification and that applying biomarkers in a manner that is informed by cytomolecular profiling outperforms a uniform biomarker approach.

Published
2022

4. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes

Author

Huang, Benjamin J, Smith, Jenny, Wang, Jim, Taghizadeh, Kassra, Leonti, Amanda R, Ries, Rhonda E, Liu, Yanling, Kolekar, Pandurang, Tarlock, Katherine, Gerbing, Robert B, Crowgey, Erin, Furlan, Scott N, Shaw, Timothy Isham, Hagiwara, Kohei, Wei, Lisa, Cooper, Todd, Gamis, Alan S, Aplenc, Richard, Kolb, Edward A, Farrar, Jason E, Triche, Timothy J, Alonzo, Todd, Ma, Xiaotu, and Meshinchi, Soheil

Subjects
Pediatric Cancer, Biotechnology, Childhood Leukemia, Genetics, Rare Diseases, Cancer, Pediatric, Hematology, Core Binding Factor beta Subunit, Humans, Leukemia, Myeloid, Acute, Myosin Heavy Chains, Oncogene Proteins, Fusion
Abstract

CBFB-MYH11 transcripts and KIT mutations predict relapse in AML. High-risk CBFB-MYH11 transcripts are associated with distinct transcriptional landscapes and upregulation of early hematopoiesis genes.

Published
2021

5. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis

Author

Zarnegar-Lumley, Sara, Alonzo, Todd A., Gerbing, Robert B., Othus, Megan, Sun, Zhuoxin, Ries, Rhonda E., Wang, Jim, Leonti, Amanda, Kutny, Matthew A., Ostronoff, Fabiana, Radich, Jerald P., Appelbaum, Frederick R., Pogosova-Agadjanyan, Era L., O’Dwyer, Kristen, Tallman, Martin S., Litzow, Mark, Atallah, Ehab, Cooper, Todd M., Aplenc, Richard A., Abdel-Wahab, Omar, Gamis, Alan S., Luger, Selina, Erba, Harry, Levine, Ross, Kolb, E. Anders, Stirewalt, Derek L., Meshinchi, Soheil, and Tarlock, Katherine

Published
2023
Full Text
View/download PDF

7. Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia

Author

van Weelderen, Romy Elise, primary, Harrison, Christine J, additional, Klein, Kim, additional, Jiang, Yilin, additional, Abrahamsson, Jonas, additional, Alonzo, Todd, additional, Aplenc, Richard, additional, Arad-Cohen, Nira, additional, Bart-Delabesse, Emmanuelle, additional, Buldini, Barbara, additional, De Moerloose, Barbara, additional, Dworzak, Michael N, additional, Elitzur, Sarah, additional, Fernández Navarro, José M, additional, Gamis, Alan S, additional, Gerbing, Robert B, additional, Goemans, Bianca F., additional, de Groot-Kruseman, Hester A, additional, Guest, Erin M., additional, Ha, Shau Yin, additional, Hasle, Henrik, additional, Kelaidi, Charikleia, additional, Lapillonne, Helene, additional, Leverger, Guy, additional, Locatelli, Franco, additional, Miyamura, Takako, additional, Noren-Nystrom, Ulrika, additional, Polychronopoulou, Sophia, additional, Rasche, Mareike, additional, Rubnitz, Jeffrey E., additional, Stary, Jan, additional, Tierens, Anne, additional, Tomizawa, Daisuke, additional, Zwaan, Michel C., additional, and Kaspers, Gertjan J L, additional

Published
2024
Full Text
View/download PDF

8. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

Author

van Dijk, Anneke D., primary, Hoff, Fieke W., additional, Qiu, Yihua, additional, Hubner, Stefan E., additional, Go, Robin L., additional, Ruvolo, Vivian R., additional, Leonti, Amanda R., additional, Gerbing, Robert B., additional, Gamis, Alan S., additional, Aplenc, Richard, additional, Kolb, Edward A., additional, Alonzo, Todd A., additional, Meshinchi, Soheil, additional, de Bont, Eveline S. J. M., additional, Horton, Terzah M., additional, and Kornblau, Steven M., additional

Published
2024
Full Text
View/download PDF

12. Prognostic Impact of Co-occurring Mutations in FLT3-ITD Pediatric Acute Myeloid Leukemia

Author

Tarlock, Katherine, primary, Gerbing, Robert B, additional, Ries, Rhonda E., additional, Smith, Jenny L., additional, Leonti, Amanda R, additional, Huang, Benjamin J., additional, Kirkey, Danielle C., additional, Robinson, Leila, additional, Peplinski, Jack H., additional, Lange, Beverly, additional, Cooper, Todd M., additional, Gamis, Alan S, additional, Kolb, E. Anders, additional, Aplenc, Richard, additional, Pollard, Jessica A., additional, and Meshinchi, Soheil, additional

Published
2024
Full Text
View/download PDF

13. Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group

Author

Shastri, Vivek M., primary, Chauhan, Lata, additional, Gbadamosi, Mohammed, additional, Alonzo, Todd A., additional, Wang, Yi-Cheng, additional, Aplenc, Richard, additional, Hirsch, Betsy A., additional, Kolb, Edward A., additional, Gamis, Alan S., additional, Meshinchi, Soheil, additional, and Lamba, Jatinder K., additional

Published
2024
Full Text
View/download PDF

14. Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431

Author

Mast, Kelley J., Taub, Jeffrey W., Alonzo, Todd A., Gamis, Alan S., Mosse, Claudio A., Mathew, Prasad, Berman, Jason N., Wang, Yi-Cheng, Jones, Heath M., Campana, Dario, Coustan-Smith, Elaine, Raimondi, Susana C., Hirsch, Betsy, Hitzler, Johann K., and Head, David R.

Subjects
Dysplasia -- Diagnosis -- Genetic aspects, Down syndrome -- Diagnosis -- Genetic aspects, Cytogenetics -- Comparative analysis -- Genetic aspects -- Reports, Acute myelocytic leukemia -- Genetic aspects -- Diagnosis, Explosions, Displays (Marketing), Myeloid leukemia, Hyperplasia, Diseases, Children, Health
Abstract

* Context.--Detailed diagnostic features of acute myeloid leukemia in Down syndrome are lacking, leading to potential misdiagnoses as standard acute myeloid leukemia occurring in patients with Down syndrome. Objective.--To evaluate diagnostic features of acute myeloid leukemia and myelodysplastic syndrome in patients with Down syndrome. Design.--Diagnostic bone marrow samples from 163 patients enrolled in the Children's Oncology Group study AAML0431 were evaluated by using central morphologic review and institutional immunophenotyping. Results were compared to overall survival, event-free survival, GATA1 mutation status, cytogenetics, and minimal residual disease results. Results.--Sixty myelodysplastic syndrome and 103 acute myeloid leukemia samples were reviewed. Both had distinctive features compared to those of patients without Down syndrome. They showed megakaryocytic and erythroid but little myeloid dysplasia, and marked megakaryocytic hyperplasia with unusual megakaryocyte morphology. In acute myeloid leukemia cases, megakaryoblastic differentiation of blasts was most common (54 of 103, 52%); other cases showed erythroblastic (11 of 103, 11%), mixed erythroid/megakaryoblastic (20 of 103, 19%), or no differentiation (10 of 103, 10%). Myelodysplastic syndrome and acute myeloid leukemia cases had similar event-free survival and overall survival. Leukemic subgroups showed interesting, but not statistically significant, trends for survival and minimal residual disease. Cases with institutional diagnoses of French American British M1-5 morphology showed typical features of Down syndrome disease, with survival approaching that of other cases. Conclusions.--Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome-related subtypes of acute myeloid leukemia and myelodysplastic syndrome. (Arch Pathol Lab Med. 2020;144:466-472; doi: 10.5858/arpa.2018-0526-OA), Down syndrome (DS) is a common genetic disorder, occurring in approximately 1 in 700 births. (1) The incidence of acute leukemia, both myeloid (AML) and lymphoid (ALL), is markedly increased [...]

Published
2020
Full Text
View/download PDF

15. Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells

Author

Perry, John M., Tao, Fang, Roy, Anuradha, Lin, Tara, He, Xi C., Chen, Shiyuan, Lu, Xiuling, Nemechek, Jacqelyn, Ruan, Linhao, Yu, Xiazhen, Dukes, Debra, Moran, Andrea, Pace, Jennifer, Schroeder, Kealan, Zhao, Meng, Venkatraman, Aparna, Qian, Pengxu, Li, Zhenrui, Hembree, Mark, Paulson, Ariel, He, Zhiquan, Xu, Dong, Tran, Thanh-Huyen, Deshmukh, Prashant, Nguyen, Chi Thanh, Kasi, Rajeswari M., Ryan, Robin, Broward, Melinda, Ding, Sheng, Guest, Erin, August, Keith, Gamis, Alan S., Godwin, Andrew, Sittampalam, G. Sitta, Weir, Scott J., and Li, Linheng

Published
2020
Full Text
View/download PDF

17. Neonatal Leukemia

Author

Guest, Erin M., primary, Garnett, Catherine, additional, Roberts, Irene, additional, and Gamis, Alan S., additional

Published
2021
Full Text
View/download PDF

21. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

Author

Bolouri, Hamid, Farrar, Jason E, Triche, Timothy, Jr, Ries, Rhonda E, Lim, Emilia L, Alonzo, Todd A, Ma, Yussanne, Moore, Richard, Mungall, Andrew J, Marra, Marco A, Zhang, Jinghui, Ma, Xiaotu, Liu, Yu, Liu, Yanling, Auvil, Jaime M Guidry, Davidsen, Tanja M, Gesuwan, Patee, Hermida, Leandro C, Salhia, Bodour, Capone, Stephen, Ramsingh, Giridharan, Zwaan, Christian Michel, Noort, Sanne, Piccolo, Stephen R, Kolb, E Anders, Gamis, Alan S, Smith, Malcolm A, Gerhard, Daniela S, and Meshinchi, Soheil

Subjects
Methylation -- Comparative analysis -- Research, DNA sequencing -- Physiological aspects -- Research, Gene mutation -- Health aspects -- Research, Pediatrics -- Research, Acute myelocytic leukemia -- Genetic aspects -- Research, Biological sciences, Health
Abstract

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG-National Cancer Institute (NCI) TARGET AML initiative assessed cases by whole-genome, targeted DNA, mRNA and microRNA sequencing and CpG methylation profiling. Validated DNA variants corresponded to diverse, infrequent mutations, with fewer than 40 genes mutated in [greater than] 2% of cases. In contrast, somatic structural variants, including new gene fusions and focal deletions of MBNL1, ZEB2 and ELF1, were disproportionately prevalent in young individuals as compared to adults. Conversely, mutations in DNMT3A and TP53, which were common in adults, were conspicuously absent from virtually all pediatric cases. New mutations in GATA2, FLT3 and CBL and recurrent mutations in MYC-ITD, NRAS, KRAS and WT1 were frequent in pediatric AML. Deletions, mutations and promoter DNA hypermethylation convergently impacted Wnt signaling, Polycomb repression, innate immune cell interactions and a cluster of zinc finger-encoding genes associated with KMT2A rearrangements. These results highlight the need for and facilitate the development of age-tailored targeted therapies for the treatment of pediatric AML., Author(s): Hamid Bolouri (corresponding author) [1]; Jason E Farrar [2]; Timothy Triche, Jr [3]; Rhonda E Ries [4]; Emilia L Lim [5]; Todd A Alonzo [6, 7]; Yussanne Ma [5]; [...]

Published
2018
Full Text
View/download PDF

22. Supplementary Figures from Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

Author

Smith, Jenny L., primary, Ries, Rhonda E., primary, Hylkema, Tiffany, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Santaguida, Marianne T., primary, Eidenschink Brodersen, Lisa, primary, Pardo, Laura, primary, Cummings, Carrie L., primary, Loeb, Keith R., primary, Le, Quy, primary, Imren, Suzan, primary, Leonti, Amanda R., primary, Gamis, Alan S., primary, Aplenc, Richard, primary, Kolb, E. Anders, primary, Farrar, Jason E., primary, Triche, Timothy J., primary, Nguyen, Cu, primary, Meerzaman, Daoud, primary, Loken, Michael R., primary, Oehler, Vivian G., primary, Bolouri, Hamid, primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure 1 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Sung, Lillian, primary, Pollard, Jessica A., primary, Aplenc, Richard, primary, Loken, Michael R., primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

25. Table S1 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Wang, Yi-Cheng, primary, Gerbing, Robert B., primary, Ries, Rhonda, primary, Loken, Michael R., primary, Pardo, Laura, primary, Hylkema, Tiffany, primary, Joaquin, Jason, primary, Sarukkai, Leela, primary, Raimondi, Susana C., primary, Hirsch, Betsy, primary, Sung, Lillian, primary, Aplenc, Richard, primary, Bernstein, Irwin, primary, Gamis, Alan S., primary, Meshinchi, Soheil, primary, and Pollard, Jessica A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods from Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

Author

Smith, Jenny L., primary, Ries, Rhonda E., primary, Hylkema, Tiffany, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Santaguida, Marianne T., primary, Eidenschink Brodersen, Lisa, primary, Pardo, Laura, primary, Cummings, Carrie L., primary, Loeb, Keith R., primary, Le, Quy, primary, Imren, Suzan, primary, Leonti, Amanda R., primary, Gamis, Alan S., primary, Aplenc, Richard, primary, Kolb, E. Anders, primary, Farrar, Jason E., primary, Triche, Timothy J., primary, Nguyen, Cu, primary, Meerzaman, Daoud, primary, Loken, Michael R., primary, Oehler, Vivian G., primary, Bolouri, Hamid, primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 2 from Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Loken, Michael R., primary, Gerbing, Robert B., primary, Ries, Rhonda E., primary, Aplenc, Richard, primary, Sung, Lillian, primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Kahwash, Samir B., primary, McKenney, Amy, primary, Kolb, E. Anders, primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 2 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Sung, Lillian, primary, Pollard, Jessica A., primary, Aplenc, Richard, primary, Loken, Michael R., primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

34. Data from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Table 2 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Figure 2 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

37. Supplemental Table 3 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table 1 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

39. Figure S1 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Wang, Yi-Cheng, primary, Gerbing, Robert B., primary, Ries, Rhonda, primary, Loken, Michael R., primary, Pardo, Laura, primary, Hylkema, Tiffany, primary, Joaquin, Jason, primary, Sarukkai, Leela, primary, Raimondi, Susana C., primary, Hirsch, Betsy, primary, Sung, Lillian, primary, Aplenc, Richard, primary, Bernstein, Irwin, primary, Gamis, Alan S., primary, Meshinchi, Soheil, primary, and Pollard, Jessica A., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Loken, Michael R., primary, Gerbing, Robert B., primary, Ries, Rhonda E., primary, Aplenc, Richard, primary, Sung, Lillian, primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Kahwash, Samir B., primary, McKenney, Amy, primary, Kolb, E. Anders, primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure 4 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 4 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Sung, Lillian, primary, Pollard, Jessica A., primary, Aplenc, Richard, primary, Loken, Michael R., primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 3 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Sung, Lillian, primary, Pollard, Jessica A., primary, Aplenc, Richard, primary, Loken, Michael R., primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 3 from Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

Author

Farrar, Jason E., primary, Schuback, Heather L., primary, Ries, Rhonda E., primary, Wai, Daniel, primary, Hampton, Oliver A., primary, Trevino, Lisa R., primary, Alonzo, Todd A., primary, Guidry Auvil, Jaime M., primary, Davidsen, Tanja M., primary, Gesuwan, Patee, primary, Hermida, Leandro, primary, Muzny, Donna M., primary, Dewal, Ninad, primary, Rustagi, Navin, primary, Lewis, Lora R., primary, Gamis, Alan S., primary, Wheeler, David A., primary, Smith, Malcolm A., primary, Gerhard, Daniela S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Tables from Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

Author

Smith, Jenny L., primary, Ries, Rhonda E., primary, Hylkema, Tiffany, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Santaguida, Marianne T., primary, Eidenschink Brodersen, Lisa, primary, Pardo, Laura, primary, Cummings, Carrie L., primary, Loeb, Keith R., primary, Le, Quy, primary, Imren, Suzan, primary, Leonti, Amanda R., primary, Gamis, Alan S., primary, Aplenc, Richard, primary, Kolb, E. Anders, primary, Farrar, Jason E., primary, Triche, Timothy J., primary, Nguyen, Cu, primary, Meerzaman, Daoud, primary, Loken, Michael R., primary, Oehler, Vivian G., primary, Bolouri, Hamid, primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Author

Tarlock, Katherine, primary, Alonzo, Todd A., primary, Gerbing, Robert B., primary, Raimondi, Susana C., primary, Hirsch, Betsy A., primary, Sung, Lillian, primary, Pollard, Jessica A., primary, Aplenc, Richard, primary, Loken, Michael R., primary, Gamis, Alan S., primary, and Meshinchi, Soheil, primary

Published
2023
Full Text
View/download PDF

50. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia

Author

Bertrums, Eline J.M., Smith, Jenny L., Harmon, Lauren, Ries, Rhonda E., Wang, Yi Cheng J., Alonzo, Todd A., Menssen, Andrew J., Chisholm, Karen M., Leonti, Amanda R., Tarlock, Katherine, Ostronoff, Fabiana, Pogosova-Agadjanyan, Era L., Kaspers, Gertjan J.L., Hasle, Henrik, Dworzak, Michael, Walter, Christiane, Muhlegger, Nora, Morerio, Cristina, Pardo, Laura, Hirsch, Betsy, Raimondi, Susana, Cooper, Todd M., Aplenc, Richard, Gamis, Alan S., Kolb, Edward A., Farrar, Jason E., Stirewalt, Derek, Ma, Xiaotu, Shaw, Tim I., Furlan, Scott N., Brodersen, Lisa Eidenschink, Loken, Michael R., Van den Heuvel-Eibrink, Marry M., Zwaan, C. Michel, Triche, Timothy J., Goemans, Bianca F., Meshinchi, Soheil, Bertrums, Eline J.M., Smith, Jenny L., Harmon, Lauren, Ries, Rhonda E., Wang, Yi Cheng J., Alonzo, Todd A., Menssen, Andrew J., Chisholm, Karen M., Leonti, Amanda R., Tarlock, Katherine, Ostronoff, Fabiana, Pogosova-Agadjanyan, Era L., Kaspers, Gertjan J.L., Hasle, Henrik, Dworzak, Michael, Walter, Christiane, Muhlegger, Nora, Morerio, Cristina, Pardo, Laura, Hirsch, Betsy, Raimondi, Susana, Cooper, Todd M., Aplenc, Richard, Gamis, Alan S., Kolb, Edward A., Farrar, Jason E., Stirewalt, Derek, Ma, Xiaotu, Shaw, Tim I., Furlan, Scott N., Brodersen, Lisa Eidenschink, Loken, Michael R., Van den Heuvel-Eibrink, Marry M., Zwaan, C. Michel, Triche, Timothy J., Goemans, Bianca F., and Meshinchi, Soheil

Abstract

NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions, we performed comprehensive transcriptome, epigenome, and immunophenotypic profiling of 2,235 children and young adults with AML and identified 160 NUP98 rearrangements (7.2%), including 108 NUP98-NSD1 (4.8%), 32 NUP98-KDM5A (1.4%) and 20 NUP98-X cases (0.9%) with 13 different fusion partners. Fusion partners defined disease characteristics and biology; patients with NUP98-NSD1 or NUP98-KDM5A had distinct immunophenotypic, transcriptomic, and epigenomic profiles. Unlike the two most prevalent NUP98 fusions, NUP98-X variants are typically not cryptic. Furthermore, NUP98-X cases are associated with WT1 mutations, and have epigenomic profiles that resemble either NUP98-NSD1 or NUP98-KDM5A. Cooperating FLT3-ITD and WT1 mutations define NUP98-NSD1, and chromosome 13 aberrations are highly enriched in NUP98-KDM5A. Importantly, we demonstrate that NUP98 fusions portend dismal overall survival, with the noteworthy exception of patients bearing abnormal chromosome 13 (clinicaltrials gov. Identifiers: NCT00002798, NCT00070174, NCT00372593, NCT01371981).

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results